Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: Dr Holmes and colleagues1 reported the results of the Sirolimus-Eluting Stent vs Brachytherapy in Patients With Bare Metal In-Stent Restenosis (SISR) trial, in which they demonstrated that sirolimus-eluting stents are superior to brachytherapy in patients with in-stent restenosis. Rather than merely abandoning brachytherapy because of logistical difficulties, it would be helpful if the authors provided additional information.
Alfonso F, Sabate M. Sirolimus-Eluting Stents vs Brachytherapy for Restenosis. JAMA. 2006;296(15):1837-1838. doi:10.1001/jama.296.15.1837-c